S-S4 BMT Tandem Breakfast Symposium: Measuring Minimal Residual Disease: The Potential and Pitfalls of Next-Generation Sequencing

Track: BMT Tandem "Scientific" Meeting
Saturday, February 14, 2015: 7:15 AM-8:15 AM
Seaport A-E (Manchester Grand Hyatt)
Chair:
Frederick R. Appelbaum, MD

Disclosures:
F. R. Appelbaum, Amgen, consultant: Consultancy
Celator, consultant: Consultancy
NMDP, consultant: Consultancy
Neumedicines, consultant: Consultancy
Pfizer, consultant: Consultancy

Summary:

Supported by educational grants from Amgen, Inc., Adaptive Biotechnologies Corporation and Sequenta, Inc.

Basic Technology of Next-Generation Sequencing: A New Approach to Measuring MRD
Aaron C. Logan, MD, PhD, University of California, San Francisco

Audio File Recorded Presentation
How Does NGS Compare with Other Approaches to Measure MRD?
Frederick R. Appelbaum, MD, Fred Hutchinson Cancer Research Center

Audio File Recorded Presentation
Immune Reconstitution after Bone Marrow Transplant
Nelson J. Chao, MD, MBA, Duke University Medical Center

Audio File Recorded Presentation
See more of: BMT Tandem "Scientific" Meeting
<< Previous Session | Next Session >>